Jürg Meier
Président chez Cardiolynx AG
Profil
Jürg Meier is currently the Chairman-Supervisory Board at Cardiolynx AG and the Director at Solvias AG.
Previously, he served as the Chairman at Spexis Ltd., Director at Viron Therapeutics, Inc., Executive Director at Novartis Venture Fund, Head-Research & Development at Sandoz, Inc., Independent Member-Supervisory Board at Tecan Group AG, Principal at Sandoz Pharmaceuticals AG, and Member at Swiss National Science Foundation.
He has also held the position of Director, Head-Research & Development at Biochemie GmbH from 1983 to 1990.
Dr. Meier's education includes a graduate degree from Rensselaer Polytechnic Institute, an undergraduate degree from INSEAD, and graduate and doctorate degrees from the Swiss Federal Institute of Technology.
Dr. Meier's current job(s) include Chairman-Supervisory Board at Cardiolynx AG and Director at Solvias AG.
Postes actifs de Jürg Meier
| Sociétés | Poste | Début |
|---|---|---|
Solvias AG
 Solvias AG BiotechnologyHealth Technology Solvias AG engages in contract research, development, and manufacturing. It offers analytical, small molecule, biopharmaceutical, solid state development, catalysis technology, custom synthesis and manufacturing, and biological analysis services. The firm serves the pharmaceutical, biotech, medical devices, cosmetics, agro chemical, chemical, eletronic materials, and life sciences industries. The company was founded in 1999 and is headquartered in Kaiseraugst, Switzerland. | Directeur/Membre du Conseil | 17/05/2010 |
Cardiolynx AG
 Cardiolynx AG BiotechnologyHealth Technology Part of JFG Life Sciences Stiftung der Universität Basel, Cardiolynx AG operates as a Swiss biotechnology company. The company is based in Basel, Switzerland. | Président | 03/01/2011 |
Anciens postes connus de Jürg Meier
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Venture Fund
 Novartis Venture Fund Investment ManagersFinance Novartis Venture Fund provides early stage venture capital to companies in Europe, North America and Asia. The fund's focus is on the development of novel therapeutics and platforms, therefore it focuses on such sectors as Biotechnology and Biopharma. The fund makes seed and early stage investments ranging up to USD 30 million per company over its life. The fund makes follow-on and co-investments. | Directeur/Membre du Conseil | 01/01/2006 |
Biochemie GmbH
 Biochemie GmbH Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Biochemie GmbH is a manufacturer of drugs. The company is based in Kundl, Austria. | Directeur Technique/Scientifique/R&D | 02/01/1990 |
| Swiss National Science Foundation | Corporate Officer/Principal | - |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Directeur Technique/Scientifique/R&D | - |
Sandoz Pharmaceuticals AG
 Sandoz Pharmaceuticals AG BiotechnologyHealth Technology Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland. | Corporate Officer/Principal | - |
Formation de Jürg Meier
| Rensselaer Polytechnic Institute | Graduate Degree |
| INSEAD | Undergraduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TECAN GROUP AG | Health Technology |
| SPEXIS AG | Health Technology |
| Entreprise privées | 8 |
|---|---|
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
Biochemie GmbH
Biochemie GmbH Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Biochemie GmbH is a manufacturer of drugs. The company is based in Kundl, Austria. | Health Technology |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
Novartis Venture Fund
Novartis Venture Fund Investment ManagersFinance Novartis Venture Fund provides early stage venture capital to companies in Europe, North America and Asia. The fund's focus is on the development of novel therapeutics and platforms, therefore it focuses on such sectors as Biotechnology and Biopharma. The fund makes seed and early stage investments ranging up to USD 30 million per company over its life. The fund makes follow-on and co-investments. | Finance |
Solvias AG
Solvias AG BiotechnologyHealth Technology Solvias AG engages in contract research, development, and manufacturing. It offers analytical, small molecule, biopharmaceutical, solid state development, catalysis technology, custom synthesis and manufacturing, and biological analysis services. The firm serves the pharmaceutical, biotech, medical devices, cosmetics, agro chemical, chemical, eletronic materials, and life sciences industries. The company was founded in 1999 and is headquartered in Kaiseraugst, Switzerland. | Health Technology |
Sandoz Pharmaceuticals AG
Sandoz Pharmaceuticals AG BiotechnologyHealth Technology Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland. | Health Technology |
| Swiss National Science Foundation | |
Cardiolynx AG
Cardiolynx AG BiotechnologyHealth Technology Part of JFG Life Sciences Stiftung der Universität Basel, Cardiolynx AG operates as a Swiss biotechnology company. The company is based in Basel, Switzerland. | Health Technology |